Company: PTPI
Filing Date: 2025-02-13
Form Type: S-1/A
Source: 0001410578-25-000122
Chunk: 170

Company: Petros Pharmaceuticals, Inc.
Filing Date: 2025-02-13
Form: S-1/A
Chunk 170
---
as defined in the Warrants) that is not within the Company’s control, including not approved by the Company’s Board of Directors, the holder of a Warrant shall only be entitled to receive from the Company or any successor entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the

<div align='center'>97</div>

unexercised portion of such Warrant, that is being offered and paid to the holders of the Company’s common stock in connection with the Fundamental Transaction. Debt Vivus Note As noted above, in January 2022, the Company executed a promissory note in favor of Vivus with a principal amount of $10,201,758 in connection with the Vivus Settlement Agreement. For more information, see the section above titled “-Vivus Settlement Agreement, Promissory Note and the Security Agreement.” Cash Flows The following table summarizes our cash flows for the years ended December 31, 2023, and 2022:

|                                                     | ​ |                     |            | ​ |      |             | ​ |
| ​                                                   | ​ | For the Years Ended |            |   |      |             | ​ |
| ​                                                   | ​ |        December 31, |            |   |      |             | ​ |
|                                                     |   |                2023 |            |   | 2022 |             |   |
| Net cash used in operating activities               | ​ |                   $ | -7,626,529 | ​ |    $ | -12,797,325 | ​ |
| Net cash provided by/(used in) financing activities | ​ |                   ​ | 11,537,240 | ​ |    ​ |  -1,623,983 | ​ |
| Net increase (decrease) in cash                     | ​ |                   $ |  3,910,711 | ​ |    $ | -14,421,308 | ​ |

Cash Flows from Operating Activities Net cash used in operating activities for the year ended December 31, 2023, was $7,626,529, which primarily reflected our net loss of $8,163,188. Adjustments to reconcile net loss to net cash provided by operating activities of $88,255 consisting primarily of depreciation and amortization, change in the fair value of derivative and warrant liabilities, loss on the issuance of Series A Preferred Stock, stock-based compensation expense, noncash warrant expenses, and changes in operating assets